-

Bruker Announces SciY™ Platform of Advanced Scientific and Automation Software Solutions for the Digital Transformation of the Life Science and Biopharma Industries

ZUERICH, Switzerland--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the SciY™ platform of advanced, vendor-agnostic software solutions for data analysis, data management, research lab and bioproduction QC digitalization, and workflow automation in the life science industry and for biopharma companies. The new SciY platform combines and integrates high-performance lab software solutions for a more comprehensive, vendor-agnostic suite of software and automation solutions for life-science industry customers, primarily in the biopharma sector.

SciY is being launched by Bruker’s new Integrated Data Solutions division, in close collaboration with majority-owned software companies Mestrelab Research, Arxspan, Optimal Industrial Technologies and ZONTAL, along with biopharma automation company Optimal Industrial Automation. With its innovative, modular software solutions, the SciY product platform will streamline data acquisition, integration and interpretation, and enhance the value of data in life-science and biopharma research, development and manufacturing.

SciY encompasses a software portfolio of Electronic Lab Notebook solutions, analytical chemistry and biology solutions, Process Analytical Technologies (PAT), and scientific data management. By automating and digitalizing workflows for generating, analyzing, and utilizing scientific data, customers can achieve results faster, more cost-effectively and conveniently, enabling better and faster decision-making, with high quality, compliance, and AI machine-learning.

Dr. Santi Dominguez, President of the new Bruker Integrated Data Solutions division, commented: "By developing and utilizing the synergetic capabilities of best-in-class teams and software products at Mestrelab, ZONTAL, Arxspan, and Optimal, our SciY platform is reshaping research and development activities in the biopharma and life science industries. The SciY platform of vendor-agnostic software solutions allows the integration of our customers’ physical laboratory instruments and automation hardware with their scientific research, development and manufacturing data into a digital environment to deliver maximum value with minimum effort and disruption. We are aiming to support our clients in their digitalization to drive seamless innovation for accelerating the time to market for new drugs, to automate life-science lab and manufacturing QC processes, and to support efficacy and patient safety.”

Dr. Falko Busse, President of the Bruker BioSpin Group, added: “With SciY and our commitment to provide instrument agnostic software for automation, integration, innovation, and discovery, we enable the life-science and biopharma industry collaboration, enhance the full potential of research data, and advance the digital transformation of the life-science industry. SciY provides many digital end-to-end solutions for life-science research and development, as well as manufacturing automation and QC.”

SciY is combining advanced software technologies into a set of modular solutions to support smooth chemistry and biology experimental design, data acquisition, integration and interpretation, and the management of many analytical instruments, available from various vendors.

About SciY™

SciY is a vendor-agnostic advanced platform offering a broad range of software solutions across the life sciences research, development and manufacturing automation and QC functions – easy to integrate, flexible, user-centric and uncompromisingly performant. By streamlining data analysis and management, SciY empowers scientists and researchers, accelerates scientific discoveries and enables precise decision-making. SciY is a brand of Bruker Integrated Data Solution division that was born from collaborations and majority-acquisitions of renowned vendor-agnostic software partners. www.sciy.com

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investor:
Justin Ward
Sr. Director, Investor Relations & Corporate Development Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Media:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor:
Justin Ward
Sr. Director, Investor Relations & Corporate Development Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Media:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Corporation to Present at Upcoming Investor Conferences

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences: Wells Fargo 21st Annual Healthcare Conference in Boston, MA Wednesday, September 9, 2026 at 8:00 a.m. Eastern Time Morgan Stanley 24th Annual Global Healthcare Conference in New York City Wednesday, September 16, 2026, at 10:45 a.m. Eastern Time Bank of America Global Healthcare Conference in London, UK Tuesday, September 22, 2026, at 6:45 a....

BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion

HANAU, Germany--(BUSINESS WIRE)--Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (Nasdaq: BRKR), and Luvata Materials & Solutions, a Business Unit of Luvata Group (LUVATA) today announced a strategic collaboration to support the rapidly growing demand for superconducting materials and technologies required by next-generation magnetic confinement fusion power demonstration plant projects worldwide.The BEST-LUVATA collaboration aims to further strengthen and e...

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

BOSTON--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs® technologies and AI-driven R&D with applications in pharmaceuticals, chemicals, energy, and materials. Bruker also made a minority investment in Atinary. Financial details were not disclosed. Atinary intends to integrate Chemspeed configurable laboratory automation platforms, Bruker analytical instruments and SciY sc...
Back to Newsroom